There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CTI BioPharma (CTIC – Research Report) and Enanta Pharmaceuticals (ENTA – Research Report) with bullish sentiments.
CTI BioPharma (CTIC)
JMP Securities analyst Reni Benjamin reiterated a Buy rating on CTI BioPharma today and set a price target of $5.00. The company’s shares closed last Tuesday at $3.10.
According to TipRanks.com, Benjamin is ranked 0 out of 5 stars with an average return of
CTI BioPharma has an analyst consensus of Strong Buy, with a price target consensus of $8.33, which is a 194.3% upside from current levels. In a report released yesterday, Brookline Capital Markets also maintained a Buy rating on the stock with a $12.00 price target.
Enanta Pharmaceuticals (ENTA)
In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Enanta Pharmaceuticals, with a price target of $116.00. The company’s shares closed last Tuesday at $69.77.
According to TipRanks.com, Buchanan ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Enanta Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $85.00, a 20.9% upside from current levels. In a report issued on February 16, Robert W. Baird also maintained a Buy rating on the stock with a $130.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CTIC:
- Salesforce Reports Upbeat Q4 Results; Street Says Buy
- JMP Securities Sticks to Their Hold Rating for Mirati Therapeutics (MRTX)
- Rosenblatt Securities Thinks Elastic’s Stock is Going to Recover
- Akebia Therapeutics (AKBA) Received its Third Buy in a Row
- Stifel Nicolaus Maintains a Hold Rating on ContextLogic (WISH)